CancerDrs

Cervical Cancer clinical trials

300 actively recruiting cervical cancer trials in the United States. Largely HPV-driven. Trials span prevention, early-stage (often curable with surgery + radiation), and advanced/metastatic disease.

Data from ClinicalTrials.gov · last refreshed · Cervical Cancer stats on SEER

52
Phase 1
106
Phase 2
13
Phase 3
7
Phase 4
122
Other

Cervical Cancer by the numbers (U.S.)

13,360
Estimated new cases (2025)
4,320
Estimated deaths (2025)
68%
5-year relative survival
50
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse cervical cancer trials by state

Top trials by phase + site coverage

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
  • Banner University Medical Center - Tucson — Tucson, Arizona

+ 334 more sites in the U.S.

Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Locations:
  • Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
  • Arizona Center for Cancer Care-Peoria — Peoria, Arizona
  • Arizona Center for Cancer Care - Biltmore — Phoenix, Arizona

+ 184 more sites in the U.S.

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona

+ 102 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Locations:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • The University of Arizona Cancer Center — Tucson, Arizona
  • University of California Los Angeles — Los Angeles, California

+ 25 more sites in the U.S.

Phase 3 Recruiting Industry

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • City of Hope — Duarte, California
  • University of California at San Diego Moores Cancer Center — La Jolla, California

+ 23 more sites in the U.S.

Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Locations:
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California

+ 23 more sites in the U.S.

Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Locations:
  • Mount Sinai Comprehensive Cancer Center ( Site 6000) — Miami Beach, Florida
  • Florida Cancer Specialists - East ( Site 7000) — West Palm Beach, Florida
  • TRIALS 365 ( Site 6008) — Shreveport, Louisiana

+ 9 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…

Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Locations:
  • City of Hope — Duarte, California
  • University of Miami — Miami, Florida
  • Tampa General Hospital — Tampa, Florida

+ 5 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…

Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Locations:
  • Providence Medical Foundation — Fullerton, California
  • Henry Ford Health System — Detroit, Michigan
  • Baptist Cancer Center — Memphis, Tennessee

+ 3 more sites in the U.S.

Phase 2, Phase 3 Recruiting Academic/Other

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of…

Sponsor: Andrei Iagaru
NCT ID: NCT05891769
Locations:
  • Stanford Hospital and Clinics — Stanford, California
Phase 3 Recruiting Academic/Other

Head and Neck Cancer Study Project in the Geriatric Population

This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as …

Sponsor: Brown University
NCT ID: NCT06998069
Locations:
  • Rhode Island and The Miriam Hospitals — Providence, Rhode Island
Phase 3 Recruiting Academic/Other

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy

Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second week of radiation therapy and progresses …

Sponsor: University of California, San Francisco
NCT ID: NCT05273307
Locations:
  • University of California, San Francisco — San Francisco, California

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-11